Trial is approved for stem cell treatment for dry AMD

02/3/2012 | Wall Street Journal, The

The FDA is permitting StemCells to conduct a safety and efficacy trial of therapeutic candidate HuCNS-SC cells among patients with dry age-related macular degeneration, or AMD. Last year, testing of the adult stem cell treatment for a rare childhood brain disorder was halted because of a lack of qualified participants.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
CareFusion
Minneapolis, MN
In house Compliance Officer
Confidential
Pompano Beach, FL
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC